Skip to main content
    P

    Pharming Group NV (PHAR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.59
    -0.01 (-0.08%)

    Market Cap: $891.80M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Pharming Group NV (PHAR) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Pharming Group NV (PHAR) trades at 39.3x trailing earnings and 2.4x sales. Its P/S of 2.4x is below its 5-year median of 3.5x. Its forward P/E is 263.2x. The median P/E across 3 similar companies is 14.2x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 85.1% lower over the next year. Its free cash flow yield is 3.4%.

    MultipleValue
    P/E (trailing)39.3x
    Forward P/E263.2x
    Price to sales2.4x
    Price to book3.2x
    EV/EBITDA15.2x
    Price to FCF29.7x
    EV/FCF26.9x
    PEGN/A
    FCF yield3.4%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S2.4x3.5xN/A
    P/B3.2x4.2xN/A
    Medians of month-end values through Oct 2026: 50 to 60 months (5-year).

    Valuation History

    Over the 3 of the 6 year ends shown that have a P/E, its P/E ranged from 39.9x in 2021 to 252.4x in 2025.

    Year endPriceP/EP/SP/B
    2025$17.67252.4x3.3x4.8x
    2024$10.07N/AN/A31.0x
    2023$11.43N/A5.0x35.0x
    2022$11.03N/A4.4x3.8x
    2021$8.9439.9x3.5x3.7x
    2020$15.2097.9x6.0x8.9x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About PHAR

    What is PHAR's forward P/E ratio?

    Pharming Group NV has a forward P/E ratio of 263.2x.

    Is PHAR stock overvalued?

    GNG's valuation label for PHAR is Undervalued. Its P/E of 39.3x compares with a median of 14.2x across 3 similar companies.

    What is PHAR's price to sales ratio?

    Pharming Group NV has a price to sales ratio of 2.4x.